Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus

ABSTRACT

Nutrient intake stimulates the secretion of the gastrointestinal incretin hormones, glucagon-like peptide–1 (GLP-1) and glucose-dependent insulinoïd polypeptide (GIP), which exert glucagon-dependent insulinoïd effects and assist pancreatic insulin and glucagon in maintaining glucose homeostasis. GLP-1 also suppresses glucose-dependent glucagon secretion, slows gastric emptying, increases satiety, and reduces food intake. An impaired incretin system, characterized by decreased responsiveness to GIP and markedly reduced GLP-1 concentration, occurs in individuals with type 2 diabetes mellitus (T2DM). The administration of GLP-1 improves glycemic control, but GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase–4 (DPP-4). Exenatide, a DPP-4–resistant exendin-4 GLP-1 receptor agonist, exhibits the glucoregulatory actions of GLP-1 and reduces body weight in patients with T2DM. It may possess cardiometabolic actions with the potential to improve the cardiovascular risk profile of patients with T2DM. DPP-4 inhibitors such as sitagliptin and saxagliptin increase endogenous GLP-1 concentration and demonstrate incretin-associated glucoregulatory actions in patients with T2DM. DPP-4 inhibitors are weight neutral. A growing understanding of the role of incretin in normal insulin secretion, as well as in the pathogenesis of T2DM, may further clarify the application of incretin-based therapies in T2DM.

KEY POINTS

- The incretin effect may be responsible for up to 70% of insulin secretion following oral glucose ingestion; reduction of the incretin effect contributes to T2DM pathophysiology.
- It is unknown whether incretin defects are a cause or consequence of T2DM.
- Incretin therapies effectively lower glucose with concomitant favorable effects on body weight. GLP-1 receptor agonists reduce weight, while DPP-4 inhibitors are weight neutral.

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus

has long been understood that the pathophysiology of type 2 diabetes mellitus (T2DM) is based on the triad of progressive decline in insulin-producing pancreatic beta cells, an increase in insulin resistance, and increased hepatic glucose production. It is now evident that other factors, including defective actions of the gastrointestinal (GI) incretin hormones glucagon-like peptide–1 (GLP-1) and glucose-dependent insulinoïd polypeptide (GIP), also play significant roles. The uncontrolled hyperglycemia resulting from such defects may lead to microvascular complications, including retinopathy, neuropathy, microangiopathy, and nephropathy, and macrovascular complications, such as coronary artery disease and peripheral vascular disease.

This review explores the growing understanding of the role of the incretins in normal insulin secretion, as well as in the pathogenesis of T2DM, and examines the pathophysiologic basis for the benefits and therapeutic application of incretin-based therapies in T2DM.

THE GI SYSTEM AND GLUCOSE HOMEOSTASIS IN THE HEALTHY STATE

The GI system plays an integral role in glucose homeostasis. The observation that orally administered glucose provides a stronger insulinoïd stimulus than an intravenous glucose challenge provided insight into the regulation of plasma glucose by the GI system of healthy individuals. The incretin effect, as this is termed, may be responsible for 50% to 70% of the total insulin secreted following oral glucose intake.

Two GI peptide hormones (the incretins)—GLP-1 and GIP—were found to exert major glucoregulatory actions. Within minutes of nutrient ingestion, GLP-1 is secreted from intestinal L cells in the distal ileum and colon, while GIP is released by intestinal K cells in the duodenum and jejunum. GLP-1 and GIP trigger their insulinoïd actions by binding beta-cell receptors. GLP-1 receptors are expressed on pancreatic glucagon-containing alpha and delta cells as well as on beta cells, whereas GIP receptors are expressed primarily on beta cells. GLP-1 receptors are also expressed in the central nervous system (CNS), peripheral nervous
system, lung, heart, and GI tract, while GIP receptors are expressed in adipose tissue and the CNS. GLP-1 inhibits glucose-dependent glucagon secretion from alpha cells. In healthy individuals, fasting glucose is managed by tonic insulin/glucagon secretion, but excursions of postprandial glucose (PPG) are controlled by insulin and the incretin hormones.

Additionally, in animal studies, GLP-1 has been shown to induce the transcriptional activation of the insulin gene and insulin biosynthesis, thus increasing beta-cell proliferation and decreasing beta-cell apoptosis. GLP-1 stimulates a CNS-mediated pathway of insulin secretion, slows gastric emptying, increases CNS-mediated satiety leading to reduced food intake, indirectly increases insulin sensitivity and nutrient uptake in skeletal muscle and adipose tissue, and exerts neuroprotective effects.

Along with its insulinotropic action, GIP has been shown in animal studies to inhibit gastric acid secretion, bioregulate fat metabolism in adipocytes, increase glucagon secretion and fat deposition, increase beta-cell replication, and decrease beta-cell apoptosis. A recent study in healthy adults showed that GLP-1 concentration declined even during maximal DPP-4 inhibition, suggesting that there may be pathways of GLP-1 elimination other than DPP-4 enzymatic degradation.

**INCRETINS AND THE PATHOGENESIS OF T2DM**

Studies have shown that incretin pathways play a role in the progression of T2DM. The significant reduction in the incretin effect seen in patients with T2DM has been attributed to several factors, including impaired secretion of GLP-1, accelerated metabolism of GLP-1 and GIP, and defective responsiveness to both hormones. Many patients with T2DM also have accelerated gastric emptying that may contribute to deterioration of their glycemic control.

While GIP concentration is normal or modestly increased in patients with T2DM, the incretinotropic actions of GIP are significantly diminished. Thus, patients with T2DM have an impaired responsiveness to GIP with a possible link to GIP-receptor downregulation or desensitization.

**Are secretory defects a cause or result of T2DM?**

In contrast to GIP, the secretion of GLP-1 has been shown to be deficient in patients with T2DM. As with GIP, it is unknown to what degree this defect is a cause or consequence of T2DM. In a study of identical twins, defective GLP-1 secretion was observed only in the one sibling with T2DM, suggesting that GLP-1 secretory defects may be secondary to the development of T2DM.

Despite the diminished secretion of GLP-1 in patients with T2DM, the insulinotropic actions of GLP-1 are preserved. It has also been shown that the effects of GLP-1 on gastric emptying and glucagon secretion are maintained in patients with T2DM.

**Whether this incretin dysregulation is responsible for or is the end result of hyperglycemia remains a subject of continued investigation.** A recent study confirmed that the incretin effect is reduced in patients with T2DM, but advanced the concept that it may be a consequence of the diabetic state. Notably, impaired actions of GLP-1 and GIP and diminished concentrations of GLP-1 may be partially restored by improved glycemic control.

Recent preclinical and clinical studies continue to clarify the roles of incretin hormones in T2DM. The findings from a study of obese diabetic mice suggest that the effect of GLP-1 therapy on the long-term remission of diabetes may be caused by improvements in beta-cell function and insulin sensitivity, as well as by a reduction in gluconeogenesis in the liver.

**Incretin effect and glucose tolerance, body mass index**

Another study was conducted to evaluate quantitatively the separate impacts of obesity and hyperglycemia on the incretin effect in patients with T2DM, patients

---

**FIGURE 1. Biologic actions of GIP and GLP-1 in relation to the pathophysiology of type 2 diabetes mellitus.** GIP = glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide-1; PP = postprandial; solid arrows = potentially beneficial actions; dashed arrows = potentially harmful actions; slashed arrows = actions with no effect.


---

<table>
<thead>
<tr>
<th>GIP</th>
<th>Type 2 diabetes</th>
<th>GLP-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ineffective in type 2 diabetes</td>
<td>↑ Insulin secretion</td>
<td>↓ Preserved activity in type 2 diabetes</td>
</tr>
<tr>
<td>Glucagon secretion ↑</td>
<td>↑ Hyperglucagonemia</td>
<td>↓ Glucagon secretion</td>
</tr>
<tr>
<td>β-cell apoptosis ↓</td>
<td>β-cell apoptosis ↑</td>
<td>β-cell apoptosis ↓</td>
</tr>
<tr>
<td>β-cell replication ↑</td>
<td>β-cell replication ↓</td>
<td></td>
</tr>
<tr>
<td>Fat deposition ↑</td>
<td>↑ Obesity</td>
<td>↓ Food intake ↑</td>
</tr>
<tr>
<td>No effects</td>
<td>↑ Gastric emptying</td>
<td>↓ Body weight ↓</td>
</tr>
<tr>
<td>No effects</td>
<td>↑ Hyperlipidemia</td>
<td>↓ Triglycerides ↓ (PP)</td>
</tr>
<tr>
<td>No effects</td>
<td>↑ Insulin resistance</td>
<td>↓ Free fatty acids ↓ (PP)</td>
</tr>
</tbody>
</table>

---

**No immediate effect**

(Insulin sensitivity ↑)
with impaired glucose tolerance, and patients with normal glucose tolerance. There was a significant \((P \leq .05)\) reduction in the incretin effect in terms of total insulin secretion, beta-cell glucose sensitivity, and the GLP-1 response to oral glucose in patients with T2DM compared with individuals whose glucose tolerance was normal or impaired. Each manifestation of the incretin effect was inversely related to both glucose tolerance and body mass index in an independent, additive manner \((P \leq .05)\); thus, glucose tolerance and obesity attenuate the incretin effect on beta-cell function and GLP-1 response independently of each other.

Exogenous GLP-1 has been shown to restore the regulation of blood glucose to near-normal concentrations in patients with T2DM. Several studies of patients with T2DM have shown that synthetic GLP-1 administration induces insulin secretion, slows gastric emptying (which is accelerated in patients with T2DM), and decreases inappropriately elevated glucagon secretion. Acute GLP-1 infusion studies showed that GLP-1 improved fasting plasma glucose (FPG) and PPG concentrations; long-term studies showed that this hormone exerts euglycemic effects, leading to improvements in glycosylated hemoglobin (HbA1c), and induces weight loss.

**TARGETING FUNDAMENTAL DEFECTS OF T2DM WITH INCRETIN-BASED THERAPIES**

Recognition and a better understanding of the role of the incretins and the enzyme involved in their degradation have led to the development of two incretin-based treatments: the GLP-1 receptor agonists, which possess many of the glucoregulatory actions of incretin peptides, and the DPP-4 inhibitors. Both the GLP-1 receptor agonists and the DPP-4 inhibitors have demonstrated safety and efficacy in the management of hyperglycemia in patients with T2DM.

**GLP-1 receptor agonists**

The GLP-1 receptor agonist exenatide is a synthetic form of exendin-4 and has a unique amino acid sequence that renders it resistant to degradation by DPP-4. Exenatide has a half-life of 2.4 hours and is detectable for up to 10 hours after subcutaneous (SC) injection. It is administered BID and has been approved as monotherapy or an adjunct therapy in patients with T2DM who have inadequate glycemic control following treatment with metformin, a sulfonylurea, a thiazolidinedione (TZD), or metformin in combination with a sulfonylurea or a TZD. Exenatide has been shown to enhance glucose-dependent insulin secretion and suppress inappropriate glucagon secretion in a glucose-dependent manner, reduce food intake and body weight, and acutely improve beta-cell function by enhancing first- and second-phase insulin secretion.

In a small study involving 17 patients with T2DM, exenatide was shown to slow gastric emptying, which could be an important mechanism contributing to its beneficial effects on PPG concentration. Exenatide also has been shown to attenuate postprandial hyperglycemia, a risk factor for cardiovascular disease (CVD), by reducing endogenous glucose production by about 50% in patients with T2DM. Another mechanism for glycemic control may exist, as a recent animal study has shown that exenatide, similar to endogenous GLP-1, lowers blood glucose concentration independent of changes in pancreatic islet hormone secretion or delayed gastric emptying.

A formulation of exenatide that is administered once weekly—exenatide long-acting release (LAR)—is in clinical evaluation and under review by the US Food and Drug Administration (FDA). In a short-term study, exenatide-LAR (0.8 mg or 2.0 mg) was administered once weekly for 15 weeks to patients with T2DM whose glycemia was suboptimally controlled with metformin alone or in combination with diet and exercise. Compared with placebo, treatment with exenatide once weekly was associated with markedly reduced HbA1c, FPG, PPG, and body weight. In a larger, 30-week, phase 3 trial, Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide ONce Weekly (DURATION-1), exenatide-LAR 2 mg once weekly was compared with exenatide 10 µg BID in patients with T2DM. Exenatide-LAR once weekly was associated with a significantly greater reduction in HbA1c \((-1.9% \text{ vs } -1.5%, P = .0023)\), and with a similar low risk of hypoglycemia and reduction in body weight \((-3.7 \text{ kg vs } -3.6 \text{ kg}, P = .89)\) compared with the BID formulation.

Liraglutide, recently approved in the European Union for T2DM and also under regulatory review in the United States, is a DPP-4-resistant human analogue GLP-1 receptor agonist in clinical development that has a 97% homology to native GLP-1. In contrast to exenatide, the acetylated liraglutide molecule allows binding to serum albumin and provides resistance to DPP-4 degradation, thus prolonging the half-life of liraglutide to approximately 12 hours. Liraglutide is administered SC QD as monotherapy or in combination with other antidiabetes agents such as metformin or sulfonylurea to patients with T2DM. Liraglutide has been shown to reduce HbA1c, decrease body weight, and lead to a lower incidence of hypoglycemia compared with the sulfonylurea glimepiride.

**DPP-4 inhibitors**

Sitagliptin is a DPP-4 inhibitor indicated as monotherapy or in combination with metformin or a TZD...
in patients with T2DM with inadequate glycemic control.48–51 Given orally, sitagliptin does not bind to the GLP-1 receptor agonist and has been shown to inhibit circulating DPP-4 activity by about 80%.52,53 Sitagliptin has been associated with an approximate twofold increase in postprandial GLP-1 plasma concentrations compared with placebo in healthy human subjects and in patients with T2DM.53 Saxagliptin, another potent DPP-4 inhibitor, significantly reduced HbA1c and FPG concentrations in patients with T2DM64 with a neutral effect on weight; it was recently approved by the FDA for treatment of T2DM.55

The DPP-4 inhibitor vildagliptin is currently being used in the European Union and Latin America but has yet to receive regulatory approval in the United States.54 Alogliptin, a novel, high-affinity, high-specificity DPP-4 inhibitor currently in development, provides rapid and sustained DPP-4 inhibition and significantly reduces HbA1c, FPG, and PPG concentrations with no change in body weight in patients with T2DM.56,57

**Incretin-based therapies compared**

In a recent head-to-head crossover trial between the GLP-1 receptor agonist exenatide and the DPP-4 inhibitor sitagliptin, exenatide had a greater effect in reducing 2-hour PPG.52 Patients with T2DM who switched from sitagliptin to exenatide showed a further reduction in 2-hour PPG concentration. Exenatide was also more potent than sitagliptin in increasing insulin secretion, reducing postprandial glucagon secretion, and decreasing triglycerides.52 Finally, exenatide slowed gastric emptying and reduced caloric intake. The differences between the two incretin-based therapies and their effects on glycemic control could be attributed to the pharmacologic concentration of the GLP-1 receptor agonist exenatide that is available for GLP-1 receptor activation compared with the twofold rise in endogenous GLP-1 concentration seen with the DPP-4 inhibitor sitagliptin.52

A comparison of the actions of the GLP-1 receptor agonists and DPP-4 inhibitors in patients with T2DM is provided in [Table 1],52,58 and an overview of incretin-based therapies is presented in [Table 2].45,54,59 GLP-1 receptor agonists induce weight loss in patients with T2DM, while DPP-4 inhibitors are weight neutral.3,52–58.60 The GLP-1 receptor agonists are associated with a much higher incidence of adverse GI effects such as nausea and vomiting, presumably also attributable to the pharmacologic levels achieved.

**Effects of incretin-based therapies**

The number of people with T2DM, overweight/obesity, or CVD, alone or in combination, is approaching epidemic proportions, with the mechanisms of these conditions interrelated. Approximately 24 million Americans have diabetes, and T2DM accounts for more than 90% of these cases.61 Most patients with T2DM are not achieving HbA1c targets.62–64 About 60% of deaths among patients with T2DM are caused by CVD.65 Compounding the problem, overweight/obesity enhances the risk for CV-related morbidities in patients with diabetes.66 A cluster of metabolic disorders referred to as the metabolic syndrome (which includes hyperglycemia, measures of central obesity, and a series of significant CV risk factors) is common in patients with T2DM and CVD.67 Unfortunately, many antidiabetes drugs that successfully manage glycemic control also cause weight gain, which in theory may increase CV risk in patients with T2DM.68

Data from studies of patients with T2DM show that exenatide improves glycemic control and reduces body weight. Exenatide administered BID significantly reduced HbA1c (−0.40% to −0.86%) and weight (−1.6 kg to −2.8 kg) relative to baseline in three 30-week, placebo-controlled clinical trials.31,33,34 In subsequent 2-year, open-label extension studies, exenatide produced significant reductions from baseline in HbA1c (−0.9% at 30 weeks) and weight (−2.1 kg at 30 weeks). Both decreases were sustained through 2 years (HbA1c −1.1%, weight −4.7 kg) with a low incidence of hypoglycemia.31 Further post

**TABLE 1**

Comparison of action of GLP-1 receptor agonists and DPP-4 inhibitors in patients with type 2 diabetes mellitus

<table>
<thead>
<tr>
<th>Action</th>
<th>Injectable GLP-1 receptor agonists</th>
<th>Oral DPP-4 inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin secretion</td>
<td>Enhanced</td>
<td>Enhanced</td>
</tr>
<tr>
<td>Glucagon secretion</td>
<td>Suppressed</td>
<td>Suppressed</td>
</tr>
<tr>
<td>Postprandial hyperglycemia</td>
<td>Reduced</td>
<td>Reduced</td>
</tr>
<tr>
<td>Gastric emptying</td>
<td>Slowed significantly</td>
<td>No effect</td>
</tr>
<tr>
<td>Appetite</td>
<td>Suppressed</td>
<td>No effect</td>
</tr>
<tr>
<td>Satiety</td>
<td>Induced</td>
<td>Neutral</td>
</tr>
<tr>
<td>Body weight</td>
<td>Reduced</td>
<td>Neutral</td>
</tr>
<tr>
<td>β-cell function</td>
<td>Preservation; proinsulin/insulin ratio improved clinically</td>
<td>Preservation; proinsulin/insulin ratio improved clinically</td>
</tr>
<tr>
<td>Gastrointestinal adverse effects</td>
<td>Often</td>
<td>Rare to none</td>
</tr>
</tbody>
</table>

*Exenatide had a greater effect than sitagliptin on these parameters, based on a crossover study comparing exenatide and sitagliptin.52

DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1.

Adapted, with permission, from Journal of Managed Care Pharmacy (Triplitt C, et al. J Manag Care Pharm 2007; 13[suppl S-4]:S2–S16). Copyright © 2007 Academy of Managed Care Pharmacy. All rights reserved.
A recent study suggested that two novel pathways could be involved—one that is dependent on the known GLP-1 receptor pathway, and one that is independent of the GLP-1 receptor pathway. Correlating with observations of a potential cardioprotective effect, an infusion of recombinant GLP-1 in patients with acute myocardial infarction, when added to standard therapy, resulted in improved left ventricular function and was associated with reduced mortality. Evidence continues to accumulate for potential cardioprotective effects of the GLP-1 receptor agonists, indicating that they may have a positive impact on macrovascular complications in patients with T2DM.

**CONCLUSION**

T2DM, which is often associated with overweight and obesity, remains a significant challenge worldwide. The broad spectrum of glucoregulatory actions of the incretin hormones GLP-1 and GIP, and their importance in maintaining glucose homeostasis, have been recognized and correlated with the pathogenesis of T2DM. An improved understanding of the roles played by GLP-1 and GIP in the pathogenesis of T2DM may provide to be fully elucidated.

### TABLE 2

<table>
<thead>
<tr>
<th>Drug</th>
<th>Approved indications</th>
<th>Average HbA1c lowering (%)</th>
<th>Route of administration</th>
<th>Dosing frequency</th>
<th>Weight effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GLP-1 RECEPTOR AGONISTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exenatide BID</td>
<td>Monotherapy or adjunct to metformin, a sulfonylurea, a TZD, a combination of metformin and a sulfonylurea, or a combination of metformin and a TZD to improve glycemic control in adults with T2DM</td>
<td>0.5–1.0</td>
<td>SC</td>
<td>BID</td>
<td>↓</td>
</tr>
<tr>
<td>Exenatide LAR</td>
<td>Investigational</td>
<td>1.8–1.9</td>
<td>SC</td>
<td>QW</td>
<td>↓</td>
</tr>
<tr>
<td>Liraglutide</td>
<td>Investigational</td>
<td>0.5–1.6</td>
<td>SC</td>
<td>QD</td>
<td>↓</td>
</tr>
<tr>
<td><strong>DPP-4 INHIBITORS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with T2DM</td>
<td>0.5–0.8</td>
<td>PO</td>
<td>QD</td>
<td>↔ ↑</td>
</tr>
<tr>
<td>Saxagliptin</td>
<td>Adjunct to diet and exercise to improve glycemic control in adults with T2DM</td>
<td>0.5–0.8</td>
<td>PO</td>
<td>QD</td>
<td>↔ ↑</td>
</tr>
<tr>
<td>Vildagliptin</td>
<td>Investigational</td>
<td>0.5–0.8</td>
<td>PO</td>
<td>QD</td>
<td>↔ ↑</td>
</tr>
<tr>
<td>Alogliptin</td>
<td>Investigational</td>
<td>0.5–0.8</td>
<td>PO</td>
<td>QD</td>
<td>↔ ↑</td>
</tr>
</tbody>
</table>

*Approved for use in patients with T2DM in the European Union.*

*Approved for use in patients with T2DM in parts of the European Union and Latin America.*

**BID** = twice daily; **DPP-4** = dipeptidyl peptidase-4; **GLP-1** = glucagon-like peptide–1; **HbA1c** = glycosylated hemoglobin A1c; **LAR** = long-acting release; **PO** = orally; **QD** = once daily; **QW** = once weekly; **SC** = subcutaneous; **T2DM** = type 2 diabetes mellitus; **TZD** = thiazolidinedione

Adapted, with permission, from *The Journal of Family Practice* (www.jfponline.com).
clinicians with important details regarding the therapeutic application of incretin-based therapies, including the GLP-1 receptor agonist exenatide and the DPP-4 inhibitors sitagliptin and saxagliptin. Antidiabetes agents whose development is based on the multiple pharmacologic effects of incretins can address the multifaceted nature of T2DM and overcome some current limitations of traditional therapies, especially those related to weight. This becomes more compelling given the close link among T2DM, obesity, and increased CV risk.

■ DISCLOSURES

Dr. Freeman reported that he has received speakers’ bureau fees from GlaxoSmithKline, Merck & Co., Inc., andNovo Nordisk Inc. He reported that he did not receive an honorarium for writing this article.

Dr. Freeman reported that he wrote this article and received no assistance with content development from unnamed contributors. He reported that BlueSpark Healthcare Communications, a medical communications company, assisted with preliminary literature searches, reference verification, proofing with content development from unnamed contributors. He reported that he wrote this article and received no assistance with content development from unnamed contributors. He reported that he wrote this article and received no assistance with content development from unnamed contributors.

■ REFERENCES


Correspondence: Jeffrey S. Freeman, DO, Professor of Internal Medicine and Chairman, Division of Endocrinology and Metabolism, Philadelphia College of Osteopathic Medicine, 4190 City Ave., Suite 324, Philadelphia, PA 19131-1626; jeffreyfreemando@aol.com